Pre-made Ustekinumab benchmark antibody ( Whole mAb, anti-IL12B therapeutic antibody, Anti-CLMF/CLMF2/IL-12B/IMD28/IMD29/NKSF/NKSF2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Ustekinumab biosimilar, Whole mAb, Anti-IL12B Antibody: Anti-CLMF/CLMF2/IL-12B/IMD28/IMD29/NKSF/NKSF2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ustekinumab, sold under the brand name Stelara®, is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment of Crohn's disease, Ulcerative Colitis, Plaque Psoriasis and Psoriatic Arthritis, targeting both IL-12 and IL-23.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-605-1mg	1mg	3090	30%	2163

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Ustekinumab biosimilar, Whole mAb, Anti-IL12B Antibody: Anti-CLMF/CLMF2/IL-12B/IMD28/IMD29/NKSF/NKSF2 therapeutic antibody
INN Name	Ustekinumab
Target	IL12B
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	3hmw:HL/3hmx:HL
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2008
Year Recommended	2009
Companies	Centocor Inc;Janssen Biotech;Medarex
Conditions Approved	Crohn's disease;Plaque psoriasis;Psoriatic arthritis
Conditions Active	Ulcerative colitis;Spondylarthritis;Systemic lupus erythematosus;Atopic dermatitis
Conditions Discontinued	Multiple sclerosis;Palmoplantar pustulosis;Primary biliary cirrhosis;Rheumatoid arthritis;Sarcoidosis
Development Tech	Medarex UltiMAb Mouse